{"pmid":32489645,"pmcid":"PMC7238818","title":"Letter to the Editor regarding \"Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?\"","text":["Letter to the Editor regarding \"Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?\"","Pulm Circ","Fernandes, Timothy M","Papamatheakis, Demosthenes G","Poch, David S","Kim, Nick H","32489645"],"journal":"Pulm Circ","authors":["Fernandes, Timothy M","Papamatheakis, Demosthenes G","Poch, David S","Kim, Nick H"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489645","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1177/2045894020925761","weight":0,"_version_":1668623433698639872,"score":9.490897,"similar":[{"pmid":32426113,"pmcid":"PMC7219006","title":"Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19?","text":["Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19?","Pulm Circ","Horn, Evelyn M","Chakinala, Murali","Oudiz, Ronald","Joseloff, Elizabeth","Rosenzweig, Erika B","32426113"],"journal":"Pulm Circ","authors":["Horn, Evelyn M","Chakinala, Murali","Oudiz, Ronald","Joseloff, Elizabeth","Rosenzweig, Erika B"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426113","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1177/2045894020922799","topics":["Treatment"],"weight":1,"_version_":1667252837946490881,"score":69.05639},{"pmid":32398296,"title":"Arterial hypertension and the risk of severity and mortality of COVID-19.","text":["Arterial hypertension and the risk of severity and mortality of COVID-19.","Eur Respir J","Leiva Sisnieguez, C E","Espeche, W G","Salazar, M R","32398296"],"journal":"Eur Respir J","authors":["Leiva Sisnieguez, C E","Espeche, W G","Salazar, M R"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32398296","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1183/13993003.01148-2020","topics":["Treatment"],"weight":1,"_version_":1666714494754095104,"score":44.723656},{"pmid":32426111,"pmcid":"PMC7222260","title":"Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic.","text":["Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic.","The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary arterial hypertension, where pulmonary arterial hypertension-specific treatments are used. It is important to balance the ongoing care and evaluation of pulmonary arterial hypertension patients with \"exposure risk\" to COVID-19 for patients coming to clinic or the hospital. If there is a morbidity and mortality benefit from starting pulmonary arterial hypertension therapies, for example in a patient with high-likelihood of pulmonary arterial hypertension, then it remains important to complete the thorough evaluation. However, the COVID-19 outbreak may also represent a unique time when pulmonary hypertension experts have to weigh the risks and benefits of the diagnostic work-up including potential exposure to COVID-19 versus initiating targeted pulmonary arterial hypertension therapy in a select high-risk, high likelihood World Symposium Pulmonary Hypertension Group 1 pulmonary arterial hypertension patients. This document will highlight some of the issues facing providers, patients, and the pulmonary arterial hypertension community in real-time as the COVID-19 pandemic is evolving and is intended to share expected common clinical scenarios and best clinical practices to help the community at-large.","Pulm Circ","Ryan, John J","Melendres-Groves, Lana","Zamanian, Roham T","Oudiz, Ronald J","Chakinala, Murali","Rosenzweig, Erika B","Gomberg-Maitland, Mardi","32426111"],"abstract":["The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary arterial hypertension, where pulmonary arterial hypertension-specific treatments are used. It is important to balance the ongoing care and evaluation of pulmonary arterial hypertension patients with \"exposure risk\" to COVID-19 for patients coming to clinic or the hospital. If there is a morbidity and mortality benefit from starting pulmonary arterial hypertension therapies, for example in a patient with high-likelihood of pulmonary arterial hypertension, then it remains important to complete the thorough evaluation. However, the COVID-19 outbreak may also represent a unique time when pulmonary hypertension experts have to weigh the risks and benefits of the diagnostic work-up including potential exposure to COVID-19 versus initiating targeted pulmonary arterial hypertension therapy in a select high-risk, high likelihood World Symposium Pulmonary Hypertension Group 1 pulmonary arterial hypertension patients. This document will highlight some of the issues facing providers, patients, and the pulmonary arterial hypertension community in real-time as the COVID-19 pandemic is evolving and is intended to share expected common clinical scenarios and best clinical practices to help the community at-large."],"journal":"Pulm Circ","authors":["Ryan, John J","Melendres-Groves, Lana","Zamanian, Roham T","Oudiz, Ronald J","Chakinala, Murali","Rosenzweig, Erika B","Gomberg-Maitland, Mardi"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426111","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1177/2045894020920153","keywords":["clinical trials","mechanical ventilation","prostacyclin","pulmonary hypertension","right heart failure","therapeutics"],"topics":["Treatment"],"weight":1,"_version_":1667252837825904641,"score":41.697586}]}